Wang X., Kapoor PM., Auer PL., Dennis J., Dunning AM., Wang Q., Lush M., Michailidou K., Bolla MK., Aronson KJ., Murphy RA., Brooks-Wilson A., Lee DG., Cordina-Duverger E., Guénel P., Truong T., Mulot C., Teras LR., Patel AV., Dossus L., Kaaks R., Hoppe R., Lo W-Y., Brüning T., Hamann U., Czene K., Gabrielson M., Hall P., Eriksson M., Jung A., Becher H., Couch FJ., Larson NL., Olson JE., Ruddy KJ., Giles GG., MacInnis RJ., Southey MC., Le Marchand L., Wilkens LR., Haiman CA., Olsson H., Augustinsson A., Krüger U., Wagner P., Scott C., Winham SJ., Vachon CM., Perou CM., Olshan AF., Troester MA., Hunter DJ., Eliassen HA., Tamimi RM., Brantley K., Andrulis IL., Figueroa J., Chanock SJ., Ahearn TU., García-Closas M., Evans GD., Newman WG., van Veen EM., Howell A., Wolk A., Håkansson N., Anton-Culver H., Ziogas A., Jones ME., Orr N., Schoemaker MJ., Swerdlow AJ., Kitahara CM., Linet M., Prentice RL., Easton DF., Milne RL., Kraft P., Chang-Claude J., Lindström S.

Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values

Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.

DOI

Type

Journal

Publication Date

Volume

Keywords